Observational Study Analysing the Transcriptome and Mutational Status of Thyroid Carcinomas of Follicular Origin with Different Degrees of Malignancy
Launched by IRCCS SYNLAB SDN · Mar 12, 2025
Trial Information
Current as of May 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying thyroid cancer, specifically looking at different types of thyroid tumors that originate from follicular cells. The researchers want to understand the molecular changes that can make some thyroid cancers more aggressive and harder to treat. They will analyze tissue and blood samples from patients with varying degrees of thyroid cancer to find new markers that could help doctors identify how severe the disease is and whether it might come back after treatment. By using advanced techniques to study the genetic material in these samples, they hope to find important clues about how thyroid cancer develops and progresses.
To participate in this study, you need to be over 18 years old and have thyroid cancer of follicular origin. If you qualify, you’ll provide samples that will be analyzed to help researchers learn more about the disease. This study is currently recruiting participants, and the findings could lead to better ways to diagnose and treat thyroid cancer in the future, making treatment more personalized for each patient.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients of either sex aged \> 18 years with thyroid cancer of follicular origin.
- Exclusion Criteria:
- • Patients who do not fit the inclusion criteria.
About Irccs Synlab Sdn
IRCCS Synlab SDN is a leading clinical research organization dedicated to advancing medical science through innovative research and development. As a recognized Institute for Health Research, Synlab SDN specializes in conducting high-quality clinical trials across various therapeutic areas, aiming to improve patient outcomes and contribute to the global body of medical knowledge. With a commitment to ethical standards and regulatory compliance, Synlab SDN collaborates with healthcare professionals and industry partners to ensure the integrity and efficacy of its research initiatives, ultimately striving to bring new treatments to market swiftly and safely.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Naples, , Italy
Patients applied
Trial Officials
Giovanni Smaldone
Principal Investigator
IRCCS SYNLAB SDN
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported